248 results
SC TO-T
CTIC
CTI BioPharma Corp
25 May 23
Third party tender offer statement
6:46am
Release issued by Swedish Orphan Biovitrum AB (publ) on May 25, 2023.
(b)(1)
Commitment letter dated May 9, 2023 and accepted as of May 10, 2023 … by and among Bank of America Europe Designated Activity Company, Danske Bank A/B and Swedish Orphan Biovitrum AB (publ).
(b)(2)
Commitment letter dated May 9
SC TO-T
EX-99
CTIC
CTI BioPharma Corp
25 May 23
Third party tender offer statement
6:46am
Project Caesar (TL&RCF) - Commitment Letter - Signature page
A51083502
We acknowledge and agree to the above:
10 May 2023
/s/ Henrik Stenqvist
/s … ) - Commitment Letter - Signature page
A51083502
APPENDIX – TERM SHEET
A51083502
EXECUTION VERSION
PROJECT CAESAR - TERM SHEET
EUR 800,000,000 TERM LOAN
SC TO-T
EX-99
CTIC
CTI BioPharma Corp
25 May 23
Third party tender offer statement
6:46am
Bank of America Europe Designated Activity Company (“BoA”) and Danske Bank A/S (“Danske”), pursuant to a commitment letter entered into among Sobi, BoA … and Danske dated on May 9, 2023 and accepted as of May 10, 2023 (the “Equity Bridge Facility Commitment Letter”), and (B) €800,000,000 in committed
SC TO-T
EX-99
CTIC
CTI BioPharma Corp
25 May 23
Third party tender offer statement
6:46am
By: Patrik Wass / Oskar Lindberg
Project Caesar (Equity bridge) - Commitment Letter - Signature page
A51082974
For and on behalf of
Danske Bank A/S … Agency
By: Ming Lu / Nicholas Ahonen
Project Caesar (Equity bridge) - Commitment Letter - Signature page
A51082974
We acknowledge and agree
SC TO-C
EX-99.1
CTIC
CTI BioPharma Corp
10 May 23
Information about tender offer
5:01pm
of the acquisition, with a commitment from Investor AB to subscribe for its pro rata share of the rights issue, corresponding to approximately 34.7
SC14D9C
EX-99.1
3tziqqk
10 May 23
Written communication relating to third party tender offer
2:02pm
SC14D9C
EX-99.1
ferqv3p3uvx6wek2 l8v
10 May 23
Written communication relating to third party tender offer
1:30pm
SC14D9C
EX-2.1
fqvlz45rl slc90
10 May 23
Written communication relating to third party tender offer
1:30pm
8-K
EX-99.1
6db1xq1zzer b16
10 May 23
Tender and Support Agreement
8:05am
8-K
EX-2.1
nqok25oypasrhj69dp
10 May 23
Tender and Support Agreement
8:05am
8-K
EX-99.1
sreagc5kzc
1 Mar 22
CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia
8:02pm